PHASEBIO PHARMA Non-operating Income/Expense

Non-operating Income/Expense of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Income/Expense growth rates and interactive chart. Income or expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from operating expenses.


Highlights and Quick Summary

  • Non-operating Income/Expense for the quarter ending June 29, 2021 was $5.78 Million (a 305.69% increase compared to previous quarter)
  • Year-over-year quarterly Non-operating Income/Expense increased by 35.8%
  • Annual Non-operating Income/Expense for 2020 was $12.8 Million (a 625.44% increase from previous year)
  • Annual Non-operating Income/Expense for 2019 was $1.77 Million (a 32.71% increase from previous year)
  • Annual Non-operating Income/Expense for 2018 was $1.33 Million (a -238.57% decrease from previous year)
  • Twelve month Non-operating Income/Expense ending June 29, 2021 was $15.5 Million (a 15.19% increase compared to previous quarter)
  • Twelve month trailing Non-operating Income/Expense increased by 112.22% year-over-year
Trailing Non-operating Income/Expense for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$15.5 Million $13.5 Million $11.4 Million $7.32 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Income/Expense of PHASEBIO PHARMA

Most recent Non-operating Income/Expenseof PHAS including historical data for past 10 years.

Interactive Chart of Non-operating Income/Expense of PHASEBIO PHARMA

PHASEBIO PHARMA Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $5.78 $1.42
2020 $4.07 $4.25 $3.73 $-0.62 $12.83
2019 $-0.05 $0.2 $0.25 $0.09 $1.77
2018 $2.79 $-2.9 $-2.57 $-1.53 $1.33
2017 $-0.67 $-0.96
2016 $-0.25

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.